Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia - PubMed (original) (raw)
Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Nicolas Boissel et al. Blood. 2011.
Free article
No abstract available
Similar articles
- Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A. Thol F, et al. Blood. 2010 Jul 29;116(4):614-6. doi: 10.1182/blood-2010-03-272146. Epub 2010 Apr 26. Blood. 2010. PMID: 20421455 - IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K. Paschka P, et al. J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21. J Clin Oncol. 2010. PMID: 20567020 - Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.
Roboz GJ. Roboz GJ. Clin Adv Hematol Oncol. 2018 May;16(5):322-325. Clin Adv Hematol Oncol. 2018. PMID: 29851927 No abstract available. - IDH2 inhibition in AML: Finally progress?
Stein EM. Stein EM. Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):112-5. doi: 10.1016/j.beha.2015.10.016. Epub 2015 Oct 19. Best Pract Res Clin Haematol. 2015. PMID: 26590767 Review. - [Research Advances of IDH2 Gene Mutation in Acute Myeloid Leukemia].
Zhao YX, Shen XL. Zhao YX, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Apr;24(2):632-6. doi: 10.7534/j.issn.1009-2137.2016.02.061. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016. PMID: 27151043 Review. Chinese.
Cited by
- Molecular markers in acute myeloid leukaemia.
Kühnl A, Grimwade D. Kühnl A, et al. Int J Hematol. 2012 Aug;96(2):153-63. doi: 10.1007/s12185-012-1123-9. Epub 2012 Jul 13. Int J Hematol. 2012. PMID: 22791509 Review. - Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.
Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, Duléry R, Boyer T, Cayuela JM, Hayette S, Raffoux E, Farhat H, Boissel N, Terre C, Dombret H, Castaigne S, Preudhomme C. Renneville A, et al. Oncotarget. 2014 Feb 28;5(4):916-32. doi: 10.18632/oncotarget.1536. Oncotarget. 2014. PMID: 24659740 Free PMC article. Clinical Trial. - Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells.
Fortin J, Chiang MF, Meydan C, Foox J, Ramachandran P, Leca J, Lemonnier F, Li WY, Gams MS, Sakamoto T, Chu M, Tobin C, Laugesen E, Robinson TM, You-Ten A, Butler DJ, Berger T, Minden MD, Levine RL, Guidos CJ, Melnick AM, Mason CE, Mak TW. Fortin J, et al. Proc Natl Acad Sci U S A. 2023 Jan 24;120(4):e2208176120. doi: 10.1073/pnas.2208176120. Epub 2023 Jan 18. Proc Natl Acad Sci U S A. 2023. PMID: 36652477 Free PMC article. - Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
Fruchtman H, Avigan ZM, Waksal JA, Brennan N, Mascarenhas JO. Fruchtman H, et al. Leukemia. 2024 May;38(5):927-935. doi: 10.1038/s41375-024-02246-2. Epub 2024 Apr 10. Leukemia. 2024. PMID: 38600315 Free PMC article. Review. - The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, Thompson CB. Ward PS, et al. J Biol Chem. 2013 Feb 8;288(6):3804-15. doi: 10.1074/jbc.M112.435495. Epub 2012 Dec 21. J Biol Chem. 2013. PMID: 23264629 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous